7JUN

J&J backs Trimtech seed to GBP35.6m

2 min read

10:09UTC

Trimtech Therapeutics extended its seed round to GBP35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

← Back to OQC's £260m sets European quantum record Jump to analysis ↓

TechnologyDeveloping

Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to GBP35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture arm, and BGF, a UK growth-capital investor, added $14m and both took board seats ¹. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a GBP25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline : a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

Source Landscape

This story draws on neutral-leaning sources

At £35.6m, Trimtech's extended seed round is unusually large for the stage, closer in size to a typical UK biotech Series A than a first institutional round, reflecting how far corporate venture cheques have grown relative to traditional seed sizes.

Structurally, corporate venture arms like J&J Innovation increasingly substitute for independent Series A leads in UK biotech, which shifts the exit calculus: a founder's most likely acquirer may already sit on the board before the company has even closed its next priced round.

Consensus view: The BioIndustry Association's finance team reads J&J Innovation's board seat as a strategic option on Trimtech's protein-degrader platform, the same corporate playbook SAP used at Conduct in June , where a corporate investor bought oversight and first look rather than pure financial upside.

Counter-view: BGF, the growth-capital co-investor taking its own board seat alongside J&J, frames the move as ordinary governance discipline ahead of a future Series A, arguing not every corporate-adjacent seed extension signals an acquisition path.

Key tension: Whether Trimtech's extended seed is a prelude to J&J licensing or eventually acquiring the platform outright, or a standard governance step before an independent Series A with new lead investors.

Sources:UKTN

Mentions:Laverock Therapeutics →Johnson & Johnson Innovation (JJDC) →BGF →Cambridge Innovation Capital →Cambridge →Conduct →SAP →Trimtech Therapeutics →

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026

Read original →

Causes and effects

Caused by

Conduct takes $60m as SAP buys in

SAP's strategic stake in Conduct set the template of a corporate investor buying board-seat visibility, now repeated with J&J Innovation and BGF in Trimtech.

Occurred 17 Jun 2026

Read story →

This Event

J&J backs Trimtech seed to GBP35.6m

Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.

Different Perspectives

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.

Invest-NL

Invest-NL joined CuspAI's $450m round as a new state investor alongside Britain's Sovereign AI Unit, named in the company's own 20 July announcement. Any framing of British state capital arriving must also credit Dutch capital with the same access, since Invest-NL took the opportunity too.

Kleiner Perkins and Bezos Expeditions

Kleiner Perkins and Bezos Expeditions co-led CuspAI's $450m Series B at a $2.6bn valuation, a figure Lowdown has now reported three times since June. Silicon Valley and a family office, not a UK investor, set the price of Britain's highest-profile materials-AI company.

British Business Bank

British Business Bank proposed a £100m debt fund for aerospace suppliers at Farnborough on 20 July, co-designed with Airbus, Rolls-Royce and GKN Aerospace. It is the Bank's first non-equity instrument this cycle, aimed at suppliers who can service a loan but have no equity story, though the structure remains unfinalised.

Institute of Physics

The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.

Helsing

The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.